SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Aditxt, Inc.
Date: June 27, 2025 · CIK: 0001726711 · Accession: 0000000000-25-006786

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288211

Date
June 27, 2025
Author
Division of
Form
UPLOAD
Company
Aditxt, Inc.

Letter

Re: Aditxt, Inc. Registration Statement on Form S-1 Filed June 20, 2025 File No. 333-288211 Dear Amro Albanna:

June 27, 2025

Amro Albanna Chief Executive Officer Aditxt, Inc. 2569 Wyandotte Street, Suite 101 Mountain View, CA 94043

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Dickerson at 202-551-8013 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Richard A. Friedman, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 June 27, 2025

Amro Albanna
Chief Executive Officer
Aditxt, Inc.
2569 Wyandotte Street, Suite 101
Mountain View, CA 94043

 Re: Aditxt, Inc.
 Registration Statement on Form S-1
 Filed June 20, 2025
 File No. 333-288211
Dear Amro Albanna:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jessica Dickerson at 202-551-8013 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Richard A. Friedman, Esq.
</TEXT>
</DOCUMENT>